Back to Journals » OncoTargets and Therapy » Volume 9

Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer

Authors Gao Y, Song P, Li H, Guo H, Jia H, Zhang B

Received 10 August 2015

Accepted for publication 10 November 2015

Published 18 December 2015 Volume 2016:9 Pages 13—20

DOI https://doi.org/10.2147/OTT.S94108

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ashok Kumar Pandurangan

Peer reviewer comments 3

Editor who approved publication: Dr Faris Farassati


Yuan Gao,1,* PingPing Song,1,* Hui Li,1 HongBo Guo,1 Hui Jia,2 BaiJiang Zhang1

1Department of Thoracic Surgery, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, People’s Republic of China; 2Department of Medical Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, People’s Republic of China

*These authors contributed equally to this work

Abstract: We report a Chinese male patient with advanced stage lung squamous cell carcinoma who developed brain metastases after responding to treatment comprising six cycles of conventional chemotherapy with docetaxel and cisplatin. The patient was then treated with oral erlotinib (150 mg/day) and whole-brain radiation therapy followed by four cycles of docetaxel and carboplatin chemotherapy. The patient then received gefitinib (250 mg/day) as a maintenance therapy until the end of the follow-up period. In this patient, progression-free survival, defined as the interval from the initiation of first-line chemotherapy to the cessation of erlotinib due to progressive disease or death from any cause, was 3 months. Overall survival, defined as the interval from the initiation of first-line chemotherapy to death from any cause, was 75 months. Erlotinib was well tolerated in combination with whole-brain radiation therapy and a favorable objective response rate was observed. Furthermore, targeted drug treatment warrants consideration in patients with a negative epidermal growth factor receptor mutation status and male patients with a history of smoking.

Keywords: EGFR tyrosine kinase inhibitors, chemotherapy, non-small cell lung cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]